Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.68

€0.68

0.150%
0.001
0.150%
-

-

 
04.12.25 / Frankfurt WKN: A2DS5F / Name: Valbiotis / Stock / Biotechnology & Medical Research / Micro Cap /
Your prediction

Valbiotis Stock

The Valbiotis stock is trending slightly upwards today, with an increase of €0.001 (0.150%) compared to yesterday's price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Valbiotis stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Valbiotis in the next few years

Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Valbiotis vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Valbiotis 0.150% - - - - - -
Cerenis Therapeutics Holding S.A. -1.570% -7.457% -2.323% - - - -
Genoway S.A. Inh. -1.580% 1.220% -4.231% -32.703% -31.215% -38.060% -15.878%
Sensorion SA -5.460% -6.734% -13.438% -58.283% -53.679% -24.626% -81.284%

News

Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements